Abstract: TH-PO1113
Impact of CKD on Angiodysplasia-Related Gastrointestinal Bleeding: Incidence, Outcomes, and Readmission Risk in a National Cohort
Session Information
- Top Trainee Posters - 1
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 01:06 PM - 01:12 PM
Category: CKD (Non-Dialysis)
- 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- He, Mingyue, Temple University Hospital, Philadelphia, Pennsylvania, United States
- Shah, Ankur, Brown University Warren Alpert Medical School, Providence, Rhode Island, United States
- Wang, Yichen, Mayo Clinic in Florida, Jacksonville, Florida, United States
- Gillespie, Avrum, Temple University Hospital, Philadelphia, Pennsylvania, United States
Background
Although angiodysplasia-related gastrointestinal bleeding (AGIB) is associated with end-stage kidney disease (ESKD), its burden across the full spectrum of chronic kidney disease (CKD) remains poorly characterized. This study aimed to evaluate the incidence of AGIB hospitalizations, associated outcomes, and 30-day readmission rates across CKD stages using nationally representative inpatient and readmission data.
Methods
We conducted a retrospective cohort study using the 2022 National Inpatient Sample and Nationwide Readmissions Database. Adults hospitalized with AGIB were identified and stratified into four groups: non-CKD (NCKD), early CKD (stage 3), advanced CKD (stages 4–5), and ESKD. The primary outcome was AGIB hospitalization incidence. Secondary outcomes included in-hospital mortality, disease severity, therapeutic interventions, healthcare utilization, and 30-day readmissions. Independent risk factors were identified using multivariable regression models.
Results
In 2022, 46,670 adults were hospitalized with AGIB, representing 0.17% of all hospitalizations. CKD was an independent risk factor for AGIB, with risk increasing progressively by CKD stage: early CKD (aOR 1.42; 95% CI, 1.34–1.50), advanced CKD (aOR 1.89; 95% CI, 1.72–2.07), and ESKD (aOR 2.51; 95% CI, 2.32–2.72; all p < 0.001). The overall in-hospital mortality rate was 1.04%, with higher rates observed among CKD patients. ESKD was independently associated with increased mortality (aOR 1.87; 95% CI, 1.06–3.27), lower rates of endoscopic evaluation (aOR 0.53; 95% CI, 0.43–0.65), and prolonged hospital stays. Endoscopy was associated with reduced mortality (aOR 0.54; 95% CI, 0.32–0.92). The 30-day all-cause readmission rate was 22.3%, with recurrent AGIB as the most common reason. Readmission risk increased progressively with CKD severity.
Conclusion
CKD progression is strongly associated with increased risk of AGIB hospitalization and readmission. ESKD and lack of endoscopic evaluation were independent risk factors of in-hospital mortality. These findings underscore the need for proactive management strategies to reduce adverse outcomes in patients with CKD and ESKD.